Clinical trial · Interventional
Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
A Surgical Window Pilot Investigation of Short Term Aspirin on the Biologic and Immunologic Changes of the Fallopian Tube
NCT03771651CI-TRIAL-00103431active not recruitingEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the impact of low dose aspirin on normal fallopian tube fimbriae in women who have surgery to have their fallopian tubes removed. Participants will take a low dose of aspirin for 2 weeks before their surgery. A portion of the removed fallopian tubes will also be collected for future research and routine pathology purposes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Cancer | Malignant Fallopian Tube Neoplasm | ALIAS | 0.90 |
| Fallopian Tube Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aspirin 81 mg | Drug | Aspirin | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Aspirin
- description
- Subjects will take 81mg tablets of aspirin daily for 14 days prior to surgery for removal of fallopian tubes.
- interventionNames
- Drug: Aspirin 81 mg
Primary outcomes (3)
- measure
- Number of subjects who exhibited alterations in the fallopian tube immune microenvironment
- timeFrame
- 5 years
- description
- Immuno-cellular assays and percentages of specific immune cells will be compared to control tissue samples.
- measure
- Number of subjects who exhibited less carcinogenic potential than control specimens
- timeFrame
- 5 years
- description
- Ciliate cells from specimens will be isolated and the number of colony forming units will be compared to control samples.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Women undergoing gynecologic surgery for presumed benign indications that includes the removal of their fallopian tubes. This may include sterilization procedures, hysterectomy or partial or full adnexectomy. * Eligible women will have fulfilled their childbearing desires * Age \> 21 Considered low risk for prevalent fallopian tube cancer (not undergoing risk reducing surgery for a known BRCA mutation or other known hereditary predisposition syndrome, family history of ovarian cancer in a first degree relative. Exclusion Criteria: * Males * Women who have presumed or known gynecologic cancer * Women less than 21 years of age * Women currently on either regular aspirin therapy, non-steroidal anti-inflammatory drugs (NSAIDS), acetaminophen or chronic steroidal anti-inflammatory medications. * Women with known bleeding diathesis or bleeding disorder. * Women who do not consent for removal of both fallopian tubes. * Women with a history of gastritis or peptic ulcer disease requiring treatment. (Patients with a history of occasional H1 or H2 blocker use for gastro esophageal reflux disease are NOT excluded). * Women with reported aspirin or NSAID allergy * Women with asthma and/or nasal polyps
References
Publications (0)
Data not yet available
No reference posted for this study.